Boston Signs Out-License and Option Agreement with GSK to Advance Two Programs for Oncology and CNS Disorders

 Boston Signs Out-License and Option Agreement with GSK to Advance Two Programs for Oncology and CNS Disorders

Boston Signs Out-License and Option Agreement with GSK to Advance Two Programs for Oncology and CNS Disorders

Shots:

  • Boston will lead the development of selected programs through PoC. GSK gets an option to reacquire each program under pre-agreed terms for development and WW commercialization, after completion of POC studies
  • If GSK exercises its repurchase option, Boston to receive a one-time payment and milestones along with royalties. If GSK selects not to reacquire a program, it will be eligible to receive milestones and royalties, meanwhile Boston will continue the development & commercialization of the programs
  • The two programs include GSK3903371 and GSK3502421. The agreement follows companies’2018 collaboration for the acquisition of GSK’s 5 programs

Click here ­to­ read full press release/ article | Ref: Businesswire | Image: Businesswire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post